Elanco Animal Health (ELAN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Elanco Animal Health (ELAN) has a cash flow conversion efficiency ratio of 0.044x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($290.00 Million) by net assets ($6.59 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Elanco Animal Health market capitalisation for the company's overall valuation and market capitalisation.
Elanco Animal Health - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Elanco Animal Health's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Elanco Animal Health Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Elanco Animal Health ranked by their cash flow conversion efficiency. Explore Elanco Animal Health earnings quality ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sanmina Corporation
NASDAQ:SANM
|
0.045x |
|
WOORI FIN. GRP SP.ADR/3
F:2WGA
|
0.311x |
|
Essential Utilities Inc
NYSE:WTRG
|
0.084x |
|
Tempus AI, Inc. Class A Common Stock
NASDAQ:TEM
|
-0.017x |
|
Banco Santander (Brasil) S.A.
SA:SANB3
|
0.200x |
|
CSPC PHARMACEUT.GR. ADR4
F:CVGU
|
N/A |
|
The Cooper Companies, Inc
NASDAQ:COO
|
0.031x |
|
REXEL S.A. ADR EO 5
F:E7V0
|
N/A |
Annual Cash Flow Conversion Efficiency for Elanco Animal Health (2016–2025)
The table below shows the annual cash flow conversion efficiency of Elanco Animal Health from 2016 to 2025. View ELAN live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $6.55 Billion | $560.00 Million | 0.086x | -3.62% |
| 2024-12-31 | $6.10 Billion | $541.00 Million | 0.089x | +103.79% |
| 2023-12-31 | $6.22 Billion | $271.00 Million | 0.044x | -29.77% |
| 2022-12-31 | $7.29 Billion | $452.00 Million | 0.062x | -3.61% |
| 2021-12-31 | $7.51 Billion | $483.00 Million | 0.064x | +1429.93% |
| 2020-12-31 | $8.48 Billion | $-41.00 Million | -0.005x | -111.97% |
| 2019-12-31 | $5.55 Billion | $224.10 Million | 0.040x | -56.91% |
| 2018-12-31 | $5.20 Billion | $487.30 Million | 0.094x | +320.28% |
| 2017-12-31 | $7.79 Billion | $173.80 Million | 0.022x | +0.57% |
| 2016-12-31 | $7.03 Billion | $155.90 Million | 0.022x | -- |
About Elanco Animal Health
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide … Read more